| Style | Citing Format |
|---|---|
| MLA | Nazemipour M, Shakiba M, Mansournia MA. "Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran." The Lancet Infectious Diseases, vol. 21, no. 5, 2021, pp. 603-604. |
| APA | Nazemipour M, Shakiba M, Mansournia MA (2021). Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran. The Lancet Infectious Diseases, 21(5), 603-604. |
| Chicago | Nazemipour M, Shakiba M, Mansournia MA. "Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran." The Lancet Infectious Diseases 21, no. 5 (2021): 603-604. |
| Harvard | Nazemipour M, Shakiba M, Mansournia MA (2021) 'Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran', The Lancet Infectious Diseases, 21(5), pp. 603-604. |
| Vancouver | Nazemipour M, Shakiba M, Mansournia MA. Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran. The Lancet Infectious Diseases. 2021;21(5):603-604. |
| BibTex | @article{ author = {Nazemipour M and Shakiba M and Mansournia MA}, title = {Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran}, journal = {The Lancet Infectious Diseases}, volume = {21}, number = {5}, pages = {603-604}, year = {2021} } |
| RIS | TY - JOUR AU - Nazemipour M AU - Shakiba M AU - Mansournia MA TI - Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran JO - The Lancet Infectious Diseases VL - 21 IS - 5 SP - 603 EP - 604 PY - 2021 ER - |